FRA:FRE Fresenius SE & Co. KGaA (FRE) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free FRE Stock Alerts €27.95 -0.02 (-0.07%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range€27.89▼€28.3850-Day Range€24.54▼€27.9752-Week Range€60.16▼€80.00Volume879,482 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Fresenius SE & Co. KGaA alerts: Email Address Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Fresenius SE & Co. KGaA Stock (FRA:FRE)Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.Read More FRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FRE Stock News HeadlinesMay 2, 2024 | marketwatch.comFresenius to Sell Vamed's Rehabilitation Business to PAI PartnersMay 2, 2024 | bloomberg.comFresenius Sells Controlling Stake in Vamed Rehab Business to PAIMay 5, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 30, 2024 | finance.yahoo.comInstitutions own 30% of Fresenius SE & Co. KGaA (ETR:FRE) shares but retail investors control 43% of the companyApril 29, 2024 | finance.yahoo.comGlobal Drug Infusion System Market Size Grows Steadily at a CAGR of 6.9%: Straits ResearchApril 13, 2024 | finanznachrichten.deApheresis Market Worth $3.9 billion | MarketsandMarketsMarch 27, 2024 | uk.finance.yahoo.comGlobal Local Anesthesia Drugs Market Forecast Reveals High Demand and Expansion by 2029February 29, 2024 | barrons.comFresenius SE & Co. KGaAMay 5, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)February 28, 2024 | seekingalpha.comFresenius SE: Hoping For The Turnaround In 2024February 22, 2024 | marketwatch.comU.S. Futures Fall, European Stocks MixedFebruary 21, 2024 | msn.comHealthcare group Fresenius tops Q4 operating profit forecastFebruary 21, 2024 | marketwatch.comFresenius 4Q Rev EUR5.68BFebruary 21, 2024 | msn.comHealthcare group Fresenius tops Q4 operating profit expectationsFebruary 20, 2024 | finanznachrichten.deFresenius Medical Care delivers on commitments in a year of fundamental transformationFebruary 20, 2024 | finance.yahoo.comFresenius SE & Co. KGaA (FRE.DE)February 19, 2024 | benzinga.comA Preview Of Fresenius Medical Care's EarningsFebruary 6, 2024 | finance.yahoo.comAutotransfusion Devices Market revenue to surpass USD 400 Million by 2033, says Research NesterFebruary 6, 2024 | msn.comCVS Health Q4 earnings on deck for early WednesdayFebruary 4, 2024 | morningstar.comFresenius SE & Co KGaAFebruary 2, 2024 | msn.comCigna beats top-line and bottom-line estimates; raises FY 2024 EPS outlook and raises dividendJanuary 31, 2024 | msn.comCigna to sell Medicare business for over $3B (update)January 11, 2024 | finance.yahoo.comIs Fresenius SE & Co. KGaA (ETR:FRE) Trading At A 45% Discount?December 7, 2023 | finance.yahoo.comGlobus Medical (GMED) Down 3.1% Since Last Earnings Report: Can It Rebound?December 6, 2023 | msn.comFresenius Scraps 2023 Dividend and Bonuses to Safeguard State AidDecember 1, 2023 | morningstar.comFresenius SE & Co KGaA ADR FREANovember 21, 2023 | benzinga.comContinuous Renal Replacement Therapy Market worth $2.1 billion | MarketsandMarketsSee More Headlines Receive FRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeFRA SectorMedical Industry Medical Care Facilities Sub-IndustryN/A Current SymbolFRA:FRE CUSIPN/A CIKN/A Webwww.fresenius.de Phone+49-6172-6080FaxN/AEmployees193,865Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael Sen (Age 56)CEO, President & Chairman of Management Board - Fresenius Management SE Comp: $4.09MMs. Sara Lisa Hennicken (Age 44)CFO & Member of the Management Board - Fresenius Management SE Comp: $1.55MMr. Pierluigi AntonelliMember of Management Board of Fresenius Management SE & CEO of Fresenius KabiDr. Michael Sven Moser Ph.D. (Age 46)Member of Management Board of Fresenius Management SE Comp: $1.2MMr. Robert Moller (Age 53)Member of the Management Board of Fresenius Management SE Comp: $1.15MMr. Markus GeorgiSenior Vice President of Investor RelationsMatthias LinkSenior Vice President Corporate CommunicationsMore ExecutivesKey CompetitorsEssilor International Société AnonymeEPA:EIFielmann GroupFRA:FIEGenfitEPA:GNFTSanofiEPA:SANSartorius AktiengesellschaftFRA:SRT3View All Competitors FRE Stock Analysis - Frequently Asked Questions How have FRE shares performed in 2024? Fresenius SE & Co. KGaA's stock was trading at €28.07 at the beginning of the year. Since then, FRE shares have decreased by 0.4% and is now trading at €27.95. View the best growth stocks for 2024 here. What other stocks do shareholders of Fresenius SE & Co. KGaA own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fresenius SE & Co. KGaA investors own include Illumina (ILMN), Daimler (DAI), Endologix (ELGX), Allianz (ALV), Cambrex (CBM), Linde (LIN), Alibaba Group (BABA), General Electric (GE) and Heidelberg Materials (HEI). This page (FRA:FRE) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fresenius SE & Co. KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.